Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Metrics to compare | VKTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVKTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −24.4x | −1.5x | −0.5x | |
PEG Ratio | 2.27 | 0.03 | 0.00 | |
Price/Book | 3.1x | 2.2x | 2.6x | |
Price / LTM Sales | - | 11.9x | 2.9x | |
Upside (Analyst Target) | 313.5% | 236.3% | 66.3% | |
Fair Value Upside | Unlock | 14.1% | 10.2% | Unlock |